Olympus Corporation

OCPNF·OTC Markets OTCPK·Healthcare
Compare
11.200.00 (0.00%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close11.20
Open11.20
Day range—
52-week range8.0014.00
Off day high0.00%
Off 52-week high−20.00%
Volume2.00K
Avg. volume (3M)920
Market cap11.90B
EPS (TTM)0.4100
Forward P/E—
P/E ratio (TTM)27.32
Dividend yield1.69% (0.1900)
Beta (5Y)0.26
Shares outstanding1.06B
Short interest—
Earnings dateNov 10, 2026
Analyst target—
Profit margin7.49%

Against its peers

Compare in full ›
OCPNF 5187.T 600587.SS AMBU-B.CO GTN0.F 300633.SZ
Market cap 11.90B 8.84B 7.80B 24.20B 7.01B 9.55B
P/E (TTM) 27.3 18.2 17.1 48.3 26.3 54.8
Forward P/E — — 7.8 30.1 — 25.9
Price/book 2.5 0.5 1.0 4.0 0.2 3.2
Dividend yield 1.69% 4.33% 2.74% 0.48% 1.80% 0.83%
1-year change −9.24% +10.47% −16.57% −0.84% +22.84% −24.22%
Today 0.00% +0.27% +0.47% +8.00% +3.31% +4.12%

The closest companies by business and industry (Medical Devices). Prices may be delayed up to 20 min.

Latest news

All OCPNF news ›
@yogonetNews·Positive

Gates of Olympus: from mythology to iconic slot IP

In this article, Sharon McHugh, Director of Public Relations at Pragmatic Play, examines how Gates of Olympus has evolved from a popular slot into a multi-vertical gaming franchise, exploring its enduring appeal and continued success…

43 Rumors·Positive

New Olympus E-M1X mod claims Auto ISO up to 25,600

It would extend automatic sensitivity by two stops over the stock manual’s 6,400 ceiling—useful for maintaining shutter speed as light falls. The E-M1X is absent from the release’s tested-camera list, and required stock firmware is…

The Phoblographer·

Is the Olympus Pen F Still Worth Buying in 2026?

The Phoblographer The Phoblographer may receive affiliate compensation for products purchased using links in this article. For more information, please visit our Disclaimers page. Is the Olympus Pen F Still Worth Buying in 2026? Should You…

markets.businessinsider.com··2 outlets

UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer

Published in Therapeutic Advances in Urology, the five-year follow-up analysis builds upon previously published Olympus findings and provides extended follow-up of patients who achieved a complete response following treatment with JELMYTO.…

More from 1 other outlet
@CNWGroup·Positive

News from Olympus Corporation of the Americas A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

news News from Olympus Corporation of the Americas A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Aug…

Motley Rice·Positive

Olympus Scopes: Recalls and Lawsuits

Motley Rice - Attorneys at Law Motley Rice represents clients across many areas. Learn about the cases Motley Rice is actively representing clients in or cases that we've litigated previously. People have filed lawsuits against weight loss…

The Age Good Food·Positive

Olympus Dining

Updated October 26, 2026,first published December 27, 2024 Are we in the heavens, dining with deities on nectar and ambrosia? It feels that way, sipping on Greek wine beneath a sweeping glass oculus open to the sky, a lush bougainvillaea…

From the 4Search news index, newest first.

In the news

16mentions in 30 days
16with it in the headline
Mixedsentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance